The Journal of Immunology

J Immunol. 2025 Sep 26:vkaf252. doi: 10.1093/jimmun/vkaf252. Online ahead of print. ABSTRACT Tuberculosis (TB), a significant global health issue, needs novel therapeutic approaches to reduce its burden. Studying host-pathogen interactions provides new targets for host-directed therapeutics (HDTs). Nuclear receptors (NRs) are important master regulators of cellular function and bona fide drug targets. Herein, we identify … Read more

J Immunol. 2025 Sep 26:vkaf259. doi: 10.1093/jimmun/vkaf259. Online ahead of print. ABSTRACT Tumor-infiltrating lymphocyte (TIL) therapy is a type of adoptive immunotherapy potentially applicable to many types of solid tumors. Although gynecologic malignancies are promising targets for TIL therapy, its objective efficacy has not been established. Current TIL culture typically involves incubation of dissociated samples … Read more

J Immunol. 2025 Sep 25:vkaf212. doi: 10.1093/jimmun/vkaf212. Online ahead of print. ABSTRACT Rhesus macaques (RMs) are widely employed as a preclinical model in vaccination and infectious disease studies, yet their B cell immunobiology and immunogenetics remain ill-characterized. In this study, single-cell RNA/VDJ sequencing was conducted on peripheral blood mononuclear cell samples from 6 RMs to … Read more

J Immunol. 2025 Sep 25:vkaf237. doi: 10.1093/jimmun/vkaf237. Online ahead of print. ABSTRACT The rising emergence of antimicrobial-resistant Pseudomonas aeruginosa strains necessitates effective therapeutic strategies like antibody-based immunotherapy. Flagellin is crucial in P. aeruginosa infection development. This study evaluated the antibacterial efficacy of bivalent immunoglobulin Y (IgY) raised against both A and B flagellins. IgY’s immunoreactivity … Read more

J Immunol. 2025 Sep 24:vkaf251. doi: 10.1093/jimmun/vkaf251. Online ahead of print. ABSTRACT Graft failure (GF) following hematopoietic stem cell transplantation (HSCT) remains a major complication particularly in the setting of human leukocyte antigen (HLA)-mismatched grafts where residual host lymphocytes can drive immune-mediated rejection. While strategies to mitigate GF have been explored, such as intensified conditioning … Read more

J Immunol. 2025 Sep 22:vkaf247. doi: 10.1093/jimmun/vkaf247. Online ahead of print. ABSTRACT Obexelimab is an investigational, bifunctional humanized monoclonal antibody that inhibits B-lineage cells by binding CD19 via its Fab region and simultaneously co-engaging the inhibitory receptor FcγRIIb through a modified Fc region. Interactions between B cells and T cells specific for the same Ag … Read more

J Immunol. 2025 Sep 22:vkaf261. doi: 10.1093/jimmun/vkaf261. Online ahead of print. NO ABSTRACT PMID:40981764 | DOI:10.1093/jimmun/vkaf261

J Immunol. 2025 Sep 22:vkaf196. doi: 10.1093/jimmun/vkaf196. Online ahead of print. ABSTRACT In response to an infection, the host T cell compartment develops immunological memory to ensure rapid responses upon re-infection with the same pathogen. However, these memory responses can also modulate immune reactions to unrelated pathogens through bystander activation. Herein, T cells are activated … Read more

J Immunol. 2025 Sep 22:vkaf257. doi: 10.1093/jimmun/vkaf257. Online ahead of print. ABSTRACT Chronic inflammatory diseases are becoming more prevalent in Western countries, yet there is limited research on clinical tools for their cure. Understanding the bacteria in the gastrointestinal tract is crucial for managing these diseases, as pathogenic bacteria can lead to inflammation and cancer, … Read more

J Immunol. 2025 Sep 16:vkaf239. doi: 10.1093/jimmun/vkaf239. Online ahead of print. ABSTRACT The differentiation of CD8 T cells into effector and memory populations is guided by a combination of antigenic, costimulatory, and cytokine signals. Here we show that, within 24 h of activating naïve CD8 T cells, populations emerge with divergent patterns of interleukin (IL)-2 … Read more